MAPT and dementia: Continued evolution of these criteria resulted in the term preclinical dementia [16,17], which was intended to identify subjects with no symptoms but with positive biomarkers of amyloid β and tau pathology, with the objective of identifying those in the earliest stages who could benefit from potential disease-modifying therapies [18].